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Cationic host defense peptides are key, evolutionarily conserved
components of the innate immune system. The human cathelicidin
LL-37 is an important cationic host defense peptide up-regulated in
infection and inflammation, specifically in the human lung, and was
shown to enhance the pulmonary clearance of the opportunistic
pathogen Pseudomonas aeruginosa in vivo by as yet undefined
mechanisms. In addition to its direct microbicidal potential, LL-37
can modulate inflammation and immune mechanisms in host de-
fenseagainst infection, includingthecapacity tomodulate celldeath
pathways. We demonstrate that at physiologically relevant concen-
trationsof LL-37, this peptidepreferentially promoted the apoptosis
of infected airway epithelium, via enhanced LL-37–induced mito-
chondrial membrane depolarization and release of cytochrome c,
with activation of caspase-9 and caspase-3 and induction of apopto-
sis,whichonlyoccurred in thepresenceofbothpeptideandbacteria,
but not with either stimulus alone. This synergistic induction of
apoptosis in infected cells was caspase-dependent, contrastingwith
the caspase-independent cell death induced by supraphysiologic
levels of peptide alone. We demonstrate that the synergistic in-
duction of apoptosis by LL-37 and Pseudomonas aeruginosa required
specificbacteria–epithelial cell interactionswithwhole, livebacteria,
and bacterial invasion of the epithelial cell. We propose that the LL-
37–mediated apoptosis of infected, compromised airway epithelial
cells may represent a novel inflammomodulatory role for this
peptide in innate host defense, promoting the clearance of re-
spiratory pathogens.
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Cationic host defense peptides (CHDPs; also known as antimi-
crobial peptides) are key, conserved components of innate host
defenses. The broad-spectrum, direct microbicidal potential of
CHDPs has made these peptides attractive therapeutic agents.
However, many CHDPs were further demonstrated to exert
multiple potential immunomodulatory functions, including the
modulation of cell death, raising questions about the nature of
their primary physiologic roles and the possibility of developing
novel therapeutics with both microbicidal and immunomodula-
tory activities.
One of the CHDPs demonstrating the most significant
immunomodulatory potential to date is LL-37. This cationic,
amphipathic peptide is the predominant cleavage product of
human cationic antimicrobial peptide (hCAP)-18, the sole
human cathelicidin (reviewed by Zanetti) (1). LL-37 is stored
at high concentrations in the specific granules of neutrophils,
and is produced by epithelial cells and some leukocytes. It can
be detected in airway surface liquid, plasma, sweat, and other
body fluids, and is upregulated in response to infection and
inflammation (1, 2). In addition to direct microbicidal capabil-
ity, the modulatory potential of LL-37 is considerable, with
in vitro and in vivo studies suggesting a broad range of activities
that could modify innate inflammatory processes and adaptive
immune responses (2). The physiological significance of LL-37
to human disease is demonstrated by the increased susceptibil-
ity to infection of individuals with morbus Kostmann (in which
defective neutrophils are cathelicidin-deficient) (3), and is also
suggested by the association between hCAP-18 expression and
susceptibility to skin infections in psoriasis and atopic dermatitis
(4). In addition, studies using a mouse model deficient in
cathelin-related antimicrobial peptide (mCRAMP), the murine
ortholog of LL-37, demonstrated increased susceptibility to
infections of the skin, gastrointestinal system, urinary tract,
and cornea (5–8). Despite this clear evidence of a critical role
for cathelicidin expression in innate defense against infection,
the relative roles of the microbicidal and immunomodulatory
activities of this peptide remain unclear.
Gene therapy augmentation demonstrated that the expres-
sion of LL-37 in the murine lung can enhance the clearance of
pulmonary Pseudomonas aeruginosa (9), an important oppor-
tunistic pulmonary pathogen of immunocompromised indi-
viduals and those with cystic fibrosis (10). However, the
mechanisms underlying enhanced defense against infection in
this model remain unclear, with the concentrations of LL-37
detected unlikely to be directly microbicidal under physiolo-
gical conditions (9, 11). Multiple mechanisms are likely involved
in the host defense against lung infection with P. aeruginosa,
ranging from simple mucociliary clearance and innate micro-
bicidal components of airway surface liquid, to the activity of
professional phagocytes. In addition, the apoptosis and sub-
sequent removal of infected epithelial cells were described as
innate defense mechanisms at diverse epithelial surfaces (12–
14), required for the clearance of invasive P. aeruginosa from
the murine lung (12). Such a mechanism may be an important
component of host defenses, removing bacteria that have
evaded other defenses and invaded epithelial cells.
LL-37 was previously demonstrated to modulate cell death
pathways (15–21). We previously demonstrated that high con-
centrations of LL-37 can induce apoptosis in airway epithelial
cell lines and primary cells in vitro, and in murine airways
in vivo (15, 17). Moreover, LL-37 was shown to induce
mitochondrial depolarization in alveolar epithelial cells (18).
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However, the roles of the Bcl2-family proteins, which can
regulate mitochondrial membrane potential, and of the key
apoptosis-inducing caspase proteins in LL-37, which can induce
apoptosis of airway epithelial cells, remain uncertain. Further, it
is unclear whether LL-37–induced apoptosis might be primarily
detrimental, with overexpression of LL-37 damaging normal
epithelial integrity, or whether at much lower, more physiolog-
ical concentrations, LL-37 expression could enhance innate
defenses by promoting targeted apoptosis to facilitate the
clearance of pathogens. To address these issues, we studied
the ability of LL-37 to induce apoptosis in airway epithelial cells
infected with the invasive lung pathogen P. aeruginosa.
We demonstrate that LL-37 can induce Bax-dependent
mitochondrial membrane depolarization in airway epithelial
cells in a dose-dependent manner, with the release of cyto-
chrome c, and that this is synergistically enhanced by infection
with P. aeruginosa. However, at physiologically relevant con-
centrations of LL-37, the activation of caspase-9 and caspase-3,
and DNA fragmentation, only occurred in the presence of both
peptide and bacteria, but not with either stimulus alone. This
synergistic induction of apoptosis was caspase-dependent and
partly Bax-dependent, and required specific bacteria–epithelial
cell interaction with whole, live bacteria capable of epithelial-
cell invasion.
MATERIALS AND METHODS
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine, non-
essential amino acids (NEAAs), PBS, trypsin/EDTA, and FBS were all
purchased from PAA Laboratories (Somerset, UK). Primary normal
human bronchial epithelial (NHBE) media and growth supplements
were purchased from Lonza (Wokingham, UK). Fibronectin, BSA,
Tween-20, Luria Bertani broth, formalin, chemiluminescence peroxi-
dase substrate, and 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate hydrate were all supplied by Sigma-Aldrich (Dorset,
UK). Mouse collagen type IV (Cultrex) was purchased from Stratech
Scientific, Ltd. (Suffolk, UK). Ultroser G was obtained from Pall
Pharmaceuticals (Hampshire, UK). Precise protein polyacrylamide
gels, M-PER protein extraction reagent, and protease/phosphatase
inhibitor cocktails were supplied by Thermo Scientific (Loughborough,
UK). Vectashield Hardset mounting medium with 49,6-diamidino-
2-phenylindole (DAPI) was supplied by Vector Laboratories
(Peterborough, UK). The Bax-inhibiting peptide V5 (BIP-V5) and
Z-VAD-FMK were supplied by Merck Chemicals, Ltd. (Nottingham,
UK). Rabbit anti-human cleaved caspase-3, caspase-8, and caspase-9
antibodies (catalogue numbers 9661, 9496, and 9505, respectively),
anti-human X-linked inhibitor of apoptosis protein (XIAP) (catalogue
number 2045), anti-human pan actin (catalogue number 4968), and
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG anti-
bodies were purchased from Cell Signaling Technologies (Danvers,
MA). We extracted Pseudomonas aeruginosa PAO1 lipopolysaccha-
ride (LPS) using a 90% aqueous phenol solution at 658C and
ultracentrifugation, followed by quantification using a limulus amebo-
cyte lysate assay (Cambrex, Wokingham, UK). LL-37 (sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES; molecu-
lar weight 4,493.33) was synthesized by N-(9-fluorenyl) methoxycar-
bonyl chemistry at the Nucleic Acid/Protein Service Unit at the
University of British Columbia (Vancouver, Canada), as described
previously (22). Scrambled LL-37 control peptide (sequence
RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL) was pur-
chased from CSS-Albachem, Ltd. (East Lothian, UK). Peptides were
purified by reverse-phase high-performance liquid chromatography,
and were at least 98% pure. LL-37, and scrambled LL-37 control
peptide, were dissolved in endotoxin-free water (Sigma-Aldrich) and
stored at 2208C until further use. The concentration of peptides in
solution was determined by amino-acid analysis, and tested to ensure
that they were free of endotoxin.
Primary and Transformed Epithelial-Cell Culture
The 16HBE14o2 transformed human bronchial epithelial cells were
a kind gift from Dieter Gruenert at the University of California, San
Francisco. Cells were grown in standard submerged cultured and
maintained in DMEM supplemented with 1% L-glutamine (vol/vol),
1% NEAA (vol/vol), and 10% FBS (vol/vol). Culture flasks were coated
with a basement layer of collagen IV (5 mg/ml), fibronectin (10 mg/ml),
and BSA (100 mg/ml) before cell culture at 378C, 5% CO2. Normal
human bronchial epithelial cells from a single donor were purchased
from Lonza. Cells were grown in standard submerged culture and
maintained in bronchial epithelial growth media (Lonza), supplemented
with bronchial epithelial cell SingleQuots growth factors and supple-
ments (Lonza) as a serum substitute, in strict accordance with the
manufacturer’s instructions.
All assays were conducted in Ultroser G serum–substitute supple-
mented media, consisting of phenol red–free DMEM supplemented
with 1% Ultroser G (vol/vol), 1% L-glutamine (vol/vol), and 1%
NEAA (vol/vol).
Bacterial Strains and Culture
In addition to P. aeruginosa PAO1, these studies used the following
strains of P. aeruginosa: clinical isolate J1386 (a clonal isolate of J1385,
originally from an individual with cystic fibrosis) (23), DmexAB-oprM
mutant (a gift from Keith Poole) (24), PAO1exsATV mutant (a gift
from Dara Frank) (25), P. aeruginosa pilA mutant (a gift from Eva
Lorenz) (26), and the isogenic PAO1 control strains for these mutants.
Studies involving genetically modified bacteria were performed accord-
ing to Scientific Advisory Committee on Genetic Modification Health
and Safety Executive Certificate GM207/07.2.
All P. aeruginosa strains were grown in Luria Bertani (LB)
broth at 378C in an orbital shaker (250 rpm) overnight, to achieve
a stationary-phase suspension. Before use, bacterial suspensions
diluted 1:20 in fresh LB broth were incubated at 378C for 90 minutes
to reach log phase. Bacterial suspensions were standardized via
dilution to an optical density of 0.1 at 595 nm, using spectropho-
tometry (WPA UV 1101, Biotech Photometer; Biochrom Ltd.,
Cambridge, UK), centrifuged at 1,500 3 g for 15 minutes (keeping
supernatant where required for use in place of live bacteria), and
resuspended in PBS before immediate addition to epithelial cells.
Where required, bacteria were heat-killed (608C for 60 minutes in an
orbital shaker) or ultraviolet light (UV)-killed (exposed to a constant
UV source for 2 hours in a sealed glass Petri dish), with killing
confirmed by overnight culture. To determine the direct microbicidal
activity of LL-37, P. aeruginosa were resuspended in Ultroser G
serum–substitute supplemented media before the immediate addition
of LL-37 at the concentrations stated. After incubation for 1 hour at
378C, serial dilutions were performed, and 100-ml aliquots of these
(and the original bacterial suspension) were spread onto LB agar
plates in triplicate, and incubated overnight at 378C before counting
the number of colony-forming units (CFUs). For studies to determine
if the function of the DmexAB-oprM mutant could be rescued by
soluble factors released by PA01, PA01 was added to 16HBE14o2
cells at a multiplicity of infection (MOI) of 10:1 and incubated for 18
hours at 378C with 5% CO2. After incubation, the supernatant was
collected and filtered through a 0.22-mm filter unit. The sterility of
filtered supernatant was confirmed by culturing 50 ml on LB agar
plates for 24 hours. Filtered supernatant (1:4 dilution in treatment
medium) was simultaneously added together with LL-37 and
DmexAB-oprM to 16HBE14o2 cells, and the cells were incubated
for 1 hour and analyzed using the mitochondrial depolarization
technique.
Mitochondrial Depolarization Assay
The 16HBE14o2 cells were seeded at 2.5 3 104 cells per well in a 96-
well plate and cultured at 378C, 5% CO2. Cells were exposed to LL-37
(or scrambled LL-37 control peptide) at the concentrations described
in the presence and absence of (1) log-phase P. aeruginosa at an MOI
of 10:1; (2) heat-killed or UV-killed bacteria (MOI 10:1), P. aeruginosa
PAO1 LPS (1 mg/ml) or P. aeruginosa supernatant, all prepared as
described above; or (3) log-phase P. aeruginosa PAO1 (MOI 10:1),
separated from the epithelial cells by a Transwell semipermeable
polyester membrane with 0.4-mm pore size (Corning Life Sciences,
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Amsterdam, Netherlands), and incubated for 1 hour at 378C, 5% CO2.
All treatments were conducted in Ultroser G serum–substitute supple-
mented media. After treatments, cells were washed once with PBS
prewarmed to 378C, the supernatant was aspirated, and 50 ml of
Mitocapture solution (Cambridge Bioscience, Cambridge, UK) at
378C were added to each well, before incubation at 378C for 30 minutes
in the dark. Cells were then washed twice with PBS at 378C,
resuspended in 50 ml of Mitocapture buffer at 378C, and imaged
immediately using an Axiovert S100 inverted fluorescent microscope
(Zeiss UK, Welwyn Garden City, UK). For each membrane, at least
four random fields of view were counted with a minimum of 300 cells in
total, and the number of apoptotic cells (displaying diffuse, green
fluorescence) was expressed as a percentage of the number of healthy
cells (displaying punctate red mitochondrial fluorescence). Data were
corrected for a background level of approximately 10% positive cells
observed in control untreated samples. For inhibition studies, the
culture medium in each well was replaced with treatment medium
containing 100 mM BIP-V5 for 1 hour before treatment.
Cytochrome c Assay
The 16HBE14o2 cells were seeded at 13 106 cells per well in a six-well
plate and cultured at 378C, 5% CO2. Cells were exposed to LL-37 at
the concentrations described in the presence and absence of log-phase
P. aeruginosa PA01 (MOI 10:1), and incubated for 90 minutes at 378C,
5% CO2. Cells were washed once with PBS, and 0.5 ml of trypsin/
EDTA was added to each well to detach cells. Ultroser G serum–
substitute supplemented media (0.5 ml) was added to each well and
suspensions were centrifuged in microtubes at 850 3 g for 2 minutes.
Mitochondrial and cytosolic fractions were then prepared using a
Mitochondrial Isolation Kit (Thermo Scientific, Loughborough, UK)
according to the manufacturer’s instructions. Cytochrome c concentra-
tions in each fraction were assessed using a Cytochrome c ELISA Kit
(Merck Chemicals, Ltd.), according to the manufacturer’s protocol.
Western Immunoblotting
The 16HBE14o2 cells were seeded at 1 3 106 cells per well in six-well
plates and cultured at 378C, 5% CO2. Cells were exposed to LL-37 at
the concentrations described, in Ultroser-G serum–substitute supple-
mented media, in the presence and absence of log-phase P. aeruginosa
PA01 (MOI 10:1) and incubated for 3 hours at 378C, 5% CO2. Cells
were washed once with ice-cold PBS and lysed with 300 mL M-PER
protein extraction reagent (Thermo Scientific) containing a cocktail of
protease, phosphatase, and metalloprotease inhibitors. Protein concen-
trations were determined by bicinchoninic acid assay (Thermo Scien-
tific). Equivalent total protein concentration lysates (15–40 mg) were
resolved on either 10% or 12% precast Precise Protein polyacrylamide
gels (Thermo Scientific), transferred to polyvinylidene fluoride mem-
branes (Bio-Rad Laboratories, Ltd., Hemel Hempstead, UK), blocked
for 1 hour with Tris-buffered saline and 0.1% Tween-20 (TBST)
containing 5% skimmed milk powder (TBST/milk), and then incubated
with antibodies specific for cleaved caspase-3 (1 in 5,000 dilution),
cleaved caspase-9 (1 in 1,000 dilution), XIAP (1 in 1,000 dilution), or
pan-actin (1 in 2,000 dilution) in TBST/milk overnight at 48C.
Membranes were washed for 15 minutes in TBST and then incubated
with a 1 in 5,000 dilution of HRP-conjugated goat anti-rabbit antibody
(in TBST/milk) or a 1 in 5,000 dilution of HRP-conjugated goat anti-
mouse antibody (in TBST/milk) for 1 hour at room temperature.
Membranes were washed for 30 minutes and developed with chem-
iluminescence peroxidase substrate (Sigma-Aldrich) according to the
manufacturer’s instructions, and imaged on CL-Xposure film (Thermo
Scientific). Equal loading of protein was confirmed by examining the
expression of actin as a loading control.
In Situ Cell Death Detection by Terminal Deoxynucleotidyl
Transferase–Mediated Deoxyuridine Triphosphate Nick-End
Labeling Assay
Transwell polyester-permeable supports (pore size, 0.4 mm; diameter,
6.5 mm; Corning Life Sciences) were equilibrated for 45 minutes in
culture media (DMEM supplemented with 10% FBS [vol/vol], 1%
L-glutamine [vol/vol], and 1% NEAA [vol/vol]) before the addition of
100 ml of medium containing 2.5 3 105 16HBE14o2 cells/ml into the
apical compartment, with 600 ml culture medium in the basal compart-
ment, and cultured at 378C, 5% CO2. For primary bronchial epithelial
cell experiments, Transwell supports were equilibrated with NHBE
culture media for 45 minutes before the addition of 100 ml of NHBE
media containing 2.5 3 105 NHBE cells/ml into the apical compart-
ment, with 600 mL of NHBE culture medium in the basal compart-
ment, and cultured at 378C, 5% CO2. Before treatments, culture media
in both the apical and basal compartments were replaced with Ultroser
G serum–substitute supplemented media. Cells were exposed to LL-37
at the concentrations described in the presence and absence of log-
phase P. aeruginosa PA01 (MOI 10:1), and incubated for 6 hours at
378C, 5% CO2. Cells were fixed in 10% neutral-buffered formalin
(3.7% formaldehyde) for 10 minutes, washed once in PBS, permeabi-
lized in ice-cold 0.1% Triton X-100/0.1% sodium citrate for 3 minutes,
and washed twice with PBS. An in situ cell death detection kit (Roche
Applied Science, West Sussex, UK) was used according to the
manufacturer’s instructions. The membranes with cells were mounted
in 50 mL Vectashield Hardset (containing DAPI), and at least four
random fields of view were counted (each containing more than 100
cells), using an Axiovert S100 fluorescent microscope, and analyzed
using OpenLAB 3.0 software (Improvision/Perkin Elmer, Waltham,
MA). The number of terminal deoxynucleotide transferase dUTP nick-
end labeling (TUNEL)–positive cells was expressed as a percentage of
the number of DAPI-positive nuclei. The total number of DAPI-
positive nuclei counted for each condition was determined, to evaluate
total cell number. For inhibition studies, cells were prepared as
described, and culture medium in each well was replaced with
treatment medium containing either 100 mM Bax inhibiting peptide
V5 (Merck Chemicals, Ltd.) or 50 mM of the broad-spectrum caspase
inhibitor, Z-VAD-FMK (Merck Chemicals, Ltd.), for 1 hour before
treatment.
Gentamicin Exclusion Assay
The capacity of P. aeruginosa isolates and mutants to invade epithelial
cells was assessed using a gentamicin exclusion assay. Briefly,
16HBE14o2 cells were exposed to strains of log-phase P. aeruginosa
(MOI 10:1) for 60 minutes in Ultroser G–serum-substitute supple-
mented media. The media were removed from all wells, and cells were
incubated with fresh media for 60 minutes with or without gentamicin
(50 mg/ml) to kill extracellular bacteria. The media were then aspirated
from gentamicin-treated cells, and these cells were vigorously washed
with PBS and lysed with PBS containing 0.1% Triton X-100, and then
plated on LB agar to determine internalized bacterial numbers. Media
and/or epithelial cell lysates from wells without gentamicin were also
plated on LB agar, to determine the number of associated bacteria and
total infectious load. The CFUs were quantified by culturing overnight
on LB agar plates at 378C.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism version 5 for
Windows (GraphPad Software Inc., La Jolla, CA). Statistical signifi-
cance was assessed either using one-way ANOVA with Tukey’s post
hoc test, or two-way ANOVA with Bonferroni’s post hoc test where
appropriate. P < 0.05 was considered significant.
RESULTS
LL-37 and P. aeruginosa Synergistically Induce Epithelial
Cell Death
To determine the capacity of LL-37 to induce cell death in
infected airway epithelial cells, the human bronchial epithelial
cell line 16HBE14o2 was infected with P. aeruginosa PAO1,
with or without concurrent exposure to LL-37. These cells
were examined for nuclear DNA fragmentation by TUNEL
assay at 6 hours (Figure 1A). Pseudomonas aeruginosa alone
did not induce cell death, and LL-37 alone induced cell death
only at higher concentrations. However, concurrent exposure
to both stimuli synergistically induced significant levels of cell
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death at greater than or equal to 20 mg/ml of LL-37 (P < 0.01),
and even at an LL-37 concentration of 20 mg/ml that had no
effect alone. A control scrambled LL-37 peptide had no effect.
Total cell counts demonstrated no loss of cells during analysis
(data not shown). To confirm these observation in nontrans-
formed cells, primary human airway epithelial cells were used,
and demonstrated the same response, with significant cell
death induced in the presence of physiologically inflammatory
levels of LL-37 only when infected with P. aeruginosa PAO1
(Figure 1B).
To determine whether the cell death observed was apopto-
sis, cleavage of the key executioner caspase, caspase-3, was
determined by Western immunoblot in 16HBE14o2 cells at 3
to 6 hours after infection with P. aeruginosa PAO1, with or
without concurrent exposure to LL-37. No activation was
detected in response to LL-37 alone, or P. aeruginosa alone.
However, concurrent exposure to both stimuli resulted in
caspase-3 activation at 4 hours and thereafter (Figure 1C
and data not shown). These data indicate that the cell death
induced synergistically by LL-37 and P. aeruginosa, but not by
high concentrations of LL-37 alone, is caspase-dependent
apoptosis. This finding is supported by the observation that
preincubation with the polycaspase inhibitor Z-VAD-FMK
significantly (P < 0.001) inhibited the synergistic induction of
cell death by P. aeruginosa and LL-37 (Figure 1A), reducing it
to approximately the level induced by LL-37 alone at that
concentration.
In addition, cleavage of caspase-9 (a key cytochrome
c–activated initiator caspase) was also observed in response to
infection with P. aeruginosa PAO1, only in the presence of LL-
37 (Figure 1D). Caspase-9 activation was not detected in
response to LL-37 alone, or P. aeruginosa alone. In contrast,
the activation of caspase-8 (a key death receptor–activated
initiator caspase) was not evident (data not shown). These data
demonstrate a synergistic induction of intrinsic apoptosis-
inducing pathways.
Given the absence of caspase-3 activation in response to
concentrations of LL-37 at which peptide alone induced cell
Figure 1. LL-37 and P. aeruginosa
synergistically induce DNA fragmen-
tation and caspase activation in air-
way epithelial cells. Human bronchial
epithelial cell line 16HBE14o2 (A, C,
D) or primary human bronchial epi-
thelial cells (B) were incubated for 6
hours (A, B) or 5 hours (C, D) over
a range of LL-37 concentrations (or
scrambled LL-37 [sLL-37] at 50
mg/ml) in Ultroser G serum–substi-
tute supplemented media, in the
presence and absence of log-phase
P. aeruginosa PA01 (MOI 10:1)
added concurrently. (A, B) Cells were
treated as described, with or without
preincubation for 1 hour with the
polycaspase inhibitor Z-VAD-FMK
(50 mM), and were then fixed. Apo-
ptosis was assessed by TUNEL assay.
Four random fields of view, each
containing more than 100 cells, were
counted for each sample. and the
number of TUNEL-positive cells was
expressed as a percentage of the
number of DAPI-positive nuclei. Data
represent mean values 6 SEM, for
n > 3 independent experiments for
each condition. Two-way ANOVA
with Bonferroni post hoc test was
used to compare LL-37/P. aerugi-
nosa–treated samples with LL-37
only–treated samples at correspond-
ing concentrations, or LL-37/P. aeru-
ginosa/Z-VAD-FMK–treated samples
with LL-37/P. aeruginosa–treated sam-
ples at corresponding concentrations.
*P < 0.05, **P < 0.01. (C, D) Whole-
cell protein lysates were prepared
and analyzed by SDS-PAGE and
Western immunoblotting. Immuno-
blots were performed using anti-
bodies specific for cleaved caspase-
3, XIAP, cleaved caspase-9, or actin.
Images shown are representative of
n > 3 independent experiments.
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death, the expression levels of XIAP (a potent caspase in-
hibitor) were examined, but no effect on expression levels was
evident (Figure 1C).
Pseudomonas aeruginosa Infection of Airway Epithelial Cells
Synergistically Enhances LL-37–Mediated Mitochondrial
Depolarization and Cytochrome c Release
To determine the role of mitochondria in LL-37–induced cell
death, 16HBE14o2 cells were infected with P. aeruginosa
PAO1, with or without concurrent exposure to LL-37. After
1 hour, the mitochondrial membrane potential was determined
as an early indicator of apoptosis (Figure 2A). The LL-37 alone
induced a dose-dependent increase in mitochondrial depolar-
ization at greater than or equal to 20 mg/ml. Pseudomonas
aeruginosa alone had no effect, but synergized with LL-37 to
induce significantly greater mitochondrial depolarization than
LL-37 alone, even inducing increased depolarization at low
(10 mg/ml) LL-37 concentrations that had no effect alone (P <
0.05). Scrambled LL-37 peptide had no effect (Figure 2A). To
determine whether this synergistic effect required an initial
interaction between LL-37 and either the epithelial cell or the
bacteria, which could subsequently alter bacteria–epithelial cell
interactions, 16HBE14o2 cells were infected with P. aeruginosa
PAO1 for 1 hour, and washed before incubation with LL-37 for
1 hour. Under these conditions, the synergistic induction of
mitochondrial depolarization was still evident, and even ampli-
fied at lower LL-37 concentrations (Figure 2B). This result
indicates that infection with P. aeruginosa promotes airway
epithelial cell susceptibility to LL-37-induced apoptosis.
To evaluate the consequences of mitochondrial depolariza-
tion, the intracellular localization of cytochrome c was exam-
ined 90 minutes after 16HBE14o2 cells were infected with
P. aeruginosa PAO1, with or without concurrent exposure to
LL-37 (Figure 2C). The LL-37 alone induced a dose-dependent
relocalization of cytochrome c from the mitochondria to the
cytoplasm, reflecting the mitochondrial depolarization and
TUNEL positivity observed, and reaching significance at 50 mg/ml
LL-37 (P < 0.01). Pseudomonas aeruginosa alone had no effect,
but synergized with LL-37 to induce a highly significant trans-
location of cytochrome c at all concentrations of LL-37 tested
(P < 0.001). This latter effect was surprisingly pronounced, with
very significant translocation observed even at 10 mg/ml of LL-
37, a concentration at which significant cell death was not
evident. Effects as yet unexplained on the mitochondria under
these conditions (but not in response to peptide alone or
bacteria alone) may have led to further translocation of
cytochrome c from the mitochondria during sample prepara-
tion, with a resultant amplification of the effect observed.
Cytoplasmic cytochrome c was detected by Western immuno-
blot in response to 10–30 mg/ml LL-37 only in infected cells
(data not shown). Thus, the cytoplasmic translocation of
cytochrome c was clearly evident under these conditions.
To determine whether the LL-37–mediated induction of
apoptosis was dependent on the key proapoptotic Bcl-2 family
protein Bax, the effects of exposure to LL-37 and P. aeruginosa
on mitochondrial depolarization (Figure 3A) and DNA frag-
mentation (Figure 3B) were evaluated after preincubation with
the Bax-inhibiting peptide V5 (BIP-V5). At high concentrations
of LL-37, at which LL-37 alone induced substantial mitochon-
drial depolarization and apoptosis, the inhibition of Bax signif-
icantly (P < 0.01) and almost completely blocked these effects.
In contrast, Bax inhibition only partly inhibited the combined
effect of LL-37 and P. aeruginosa. These data demonstrate that
caspase-independent induction of cell death by LL-37 alone is
Bax-dependent. However, additional, and as yet unidentified,
components are required for the synergistic enhancement of
mitochondrial depolarization and induction of caspase-dependent
apoptosis by LL-37 in P. aeruginosa–infected cells.
Synergistic Induction of Apoptosis by LL-37 and P. aeruginosa
Requires Specific Bacteria–Epithelial Cell Interactions
with Live Bacteria
To exclude the possibility that LL-37 exerted directly micro-
bicidal effects on P. aeruginosa PAO1, bacterial viability was
determined after exposure to LL-37 over the range of concen-
trations and in the culture media used for these studies (Figure
4A). No significant, direct microbicidal activity was evident.
To examine whether the synergistic induction of apoptosis
by LL-37 and P. aeruginosa required infection with live bacteria,
and/or could result from secreted products, 16HBE14o2 cells
were exposed to a range of bacterial stimuli in the presence or
absence of concurrent exposure to 30 mg/ml LL-37, and assessed
for mitochondrial depolarization (Figure 4B). The highly sig-
nificant (P < 0.001), synergistic induction of mitochondrial
depolarization observed after exposure to live P. aeruginosa
and LL-37 was completely lost if the bacteria used were dead
(heat-killed or UV-killed), or substituted with bacterial culture
supernatant, or LPS prepared from PAO1 (1 mg/ml). Further-
more, physical separation of the epithelial cells from the
bacteria by a semipermeable membrane also completely pre-
vented this effect. These data indicate that the synergistic
induction of apoptosis by LL-37 and P. aeruginosa requires
a physical interaction between the epithelial cells and viable
bacteria, and is not simply the result of pathogen-sensing by
extracellular pattern recognition receptors.
Synergistic Induction of Apoptosis by LL-37 and P. aeruginosa
Is Isolate-Specific, and Independent of Type III Secretion
System and Pilus Expression
To exclude the possibility that the synergistic induction of
apoptosis by LL-37 and P. aeruginosa was specific to PAO1,
a clinical P. aeruginosa isolate J1386 was examined (Figure 5A).
A synergistic induction of mitochondrial depolarization was
also observed in response to this clinical isolate in the presence
of LL-37. This finding was substantially enhanced in compari-
son to that observed using the laboratory strain PAO1, with
significant effects observed in infected cells after incubation
with concentrations of LL-37 greater than or equal to 1 mg/ml
(P < 0.01). No direct microbicidal effect of LL-37 was observed
on P. aeruginosa isolate J1386 (data not shown).
To examine whether common virulence factors differentially
expressed by divergent P. aeruginosa isolates were necessary for
this effect, mutant strains of P. aeruginosa PAO1 were used
(Figures 5B and 5C). No substantial difference was evident
when comparing an ExsA mutant with a defective type III
secretion system (PAO1exsATV; Figure 5B) or a pilus mutant
(pilA mutant; Figure 5C) with their corresponding isogenic
strains. No direct microbicidal effect of LL-37 was evident in
either mutant strain (data not shown). These data demonstrate
that common determinants of virulence associated with epithe-
lial-cell interactions (pilus) and bacterially induced epithelial
cell death (type III secretion system) are not required for the
synergistic induction of apoptosis in LL-37–treated infected
epithelial cells.
Synergistic Induction of Apoptosis by LL-37 and P. aeruginosa
Requires Epithelial-Cell Internalization of Bacteria
The internalization of P. aeruginosa by airway epithelial cells
was proposed as a key component of the innate pulmonary host
defense that is defective in cystic fibrosis (27). To determine the
significance of bacterial internalization, a MexAB-OprM de-
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letion mutant (DmexAB-oprM), described as containing a defect
in its ability to invade epithelial cells (28), was used. The
16HBE14o2 cells were infected with PAO1DmexAB-oprM, or
the isogenic control, and a gentamicin-exclusion assay was
performed to determine the extent of internalization into the
epithelial cells (Figure 6A). Whereas internalization of the
isogenic strain could be clearly demonstrated, negligible in-
ternalization of the PAO1DmexAB-oprM bacteria occurred.
Furthermore, the LL-37–mediated synergistic enhancement of
apoptosis was significantly (P < 0.001) and completely lost
when using PAO1DmexAB-oprM (Figure 6B). The invasion
defect of PAO1DmexAB-oprM was previously shown to result
from the absence of a bacterial secreted factor, and can be
restored by the addition of supernatants from isogenic control
bacteria exposed to epithelial cells (28). The LL-37–mediated
synergistic enhancement of apoptosis was significantly restored
(P < 0.01) when 16HBE14o2 cells were infected with
PAO1DmexAB-oprM in the presence of both LL-37 and
supernatants from isogenic control bacteria exposed to epithe-
lial cells (Figure 6C). These data demonstrate that the epithe-
lial-cell internalization of P. aeruginosa is required to facilitate
the LL-37–mediated induction of apoptosis at physiologically
inflammatory concentrations of peptide.
DISCUSSION
Cationic host-defense peptides, including LL-37, have been
demonstrated to have multiple properties capable of modulat-
ing inflammation and immunity. The full extent of these
properties remains to be determined, but understanding the
physiological roles of CHDPs in health and disease, and their
development as antimicrobial therapeutics, is clearly significant.
Our results suggest a novel innate inflammomodulatory role for
LL-37, preferentially inducing apoptosis in infected epithelial
cells, with the potential to exert protective or detrimental
effects.
The most critical mechanisms by which cathelicidins contrib-
ute to host defense against infections remain uncertain. In various
models, LL-37 and mCRAMP exert antimicrobial effects in vivo
(5–9), despite high minimum inhibitory concentration values that
often exceed detectable physiologic levels. Recent studies impli-
cated the vitamin D–dependent up-regulation of LL-37 in the
intracellular killing of mycobacteria in mononuclear leukocytes
(29, 30), perhaps in synergy with b-defensin 4 (31), and
mCRAMP impairs the intracellular replication of Salmonella
(32). Therefore, these peptides likely have direct antimicrobial
roles where peptides are concentrated in favorable, controlled
ionic conditions, and perhaps function synergistically with other
agents. However, the function of LL-37 at epithelial surfaces, at
the peptide concentrations reported, is less clear. In lungs, hCAP-
18 was detected in bronchoalveolar lavage fluid from healthy
infants at approximately 5 mg/ml, and was found at up to
approximately 25 mg/ml and at approximately 15 mg/ml in infants
with pulmonary infections and individuals with cystic fibrosis lung
Figure 2. Pseudomonas aeruginosa infection of airway epithelial cells
synergistically enhances LL-37–mediated mitochondrial depolarization
and cytochrome c release. Human bronchial epithelial cells
(16HBE14o2) were incubated with a range of LL-37 concentrations
(or scrambled LL-37 [sLL-37] at 50 mg/ml) in Ultroser G serum–
substitute supplemented media, in the presence and absence of log-
phase P. aeruginosa PA01 (MOI 10:1). Bacteria and LL-37 were added
concurrently and incubated for 60 minutes (A) or 90 minutes (C), or
epithelial cells were preinfected with bacteria for 60 minutes, washed,
and exposed to LL-37 for 60 minutes (B). (A, B) Mitochondrial
membrane depolarization was determined using Mitocapture dye,
quantifying the percentage of apoptotic cells displaying diffuse green
fluorescence (cells with depolarized mitochondria), compared with
healthy cells displaying punctuate red fluorescence (cells with polarized
mitochondrial membranes). Four random fields of view were counted
for each sample (minimum of 300 cells per sample), and number of
apoptotic cells was expressed as a percentage of the total number of
cells. Data were corrected for a background level of approximately 10%
positive cells in control untreated samples, and plotted as mean values6
SEM, for n 5 6 (A) or n 5 3 (B) independent experiments for each
condition. Two-way ANOVA with Bonferroni post hoc test was per-
formed to determine significance. *P < 0.05, **P< 0.01, ***P < 0.001.
(C ) Cellular localization of cytochrome c was assessed by ELISA analysis
of mitochondrial fractions after subcellular fractionation. Data represent
the mean percentage of cytochrome c present in this fraction as
a proportion of total cytochrome c detected in each sample 6 SEM
for n 5 3 independent experiments, measured in duplicate for each
condition. Two-way ANOVA was performed with Bonferroni post hoc
test to compare each treatment to appropriate LL-37–free negative
control sample. **P < 0.01, ***P < 0.001.
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disease (in steady state), respectively (33, 34). At these sites,
immunomodulatory roles may be of primary significance. Indeed,
the potential significance of such activities was recently demon-
strated in terms of the in vivo protection against infection in
animal models using a synthetic CHDP derivative with no direct
antimicrobial activity in vitro (35).
A variety of CHDPs, including bovine cathelicidins and
human a-defensins, were shown to affect eukaryotic cell death
(18, 36). We previously showed that high (potentially supra-
physiologic) concentrations of LL-37 induced apoptosis in
pulmonary epithelial cells in vitro and in vivo (15, 17). However,
the mechanisms involved remain undetermined. We demon-
strate here that at these higher concentrations, LL-37 can
induce mitochondrial depolarization and cytochrome c release
Figure 3. LL-37–induced mitochondrial depolarization and DNA frag-
mentation involve Bax-dependent mechanisms. Human bronchial
epithelial cells (16HBE14o2) were incubated for 1 hour (A) or 6 hours
(B) over a range of LL-37 concentrations in Ultroser G serum–substitute
supplemented media, in the presence and absence of log-phase
P. aeruginosa PA01 (MOI 10:1) added concurrently, with or without
preincubation for 1 hour with Bax-inhibiting peptide V5 (BIP-V5;
100 mM). (A) Mitochondrial membrane depolarization was determined
using Mitocapture dye, quantifying the percentage of apoptotic cells
displaying diffuse green fluorescence (cells with depolarized mitochon-
dria), compared with healthy cells displaying punctuate red fluores-
cence (cells with polarized mitochondrial membranes). Four random
fields of view were counted for each sample (minimum of 300 cells per
sample), and the number of apoptotic cells was expressed as a per-
centage of total number of cells. Data were corrected for a background
level of approximately 10% positive cells in control untreated samples,
and plotted as mean values6 SEM, for n5 3 independent experiments
for each condition. A two-way ANOVA with Bonferroni post hoc test
was used to compare LL-37–only treated samples with LL-37/BIP-V5–
treated samples, or LL-37/P. aeruginosa–treated samples with LL-37/P.
aeruginosa/BIP-V5–treated samples at corresponding concentrations.
*P < 0.05, **P < 0.01, ***P < 0.001. (B) Cells were fixed and apoptosis
was assessed by TUNEL assay. Four random fields of view, each
containing more than 100 cells, were counted for each sample, and
the number of TUNEL-positive cells was expressed as a percentage of
the number of DAPI-positive nuclei. Data represent mean values 6
SEM, for n 5 3 independent experiments for each condition. Two-
way ANOVA with Bonferroni post hoc test was used to compare LL-37
only–treated samples with LL-37/BIP-V5–treated samples, or LL-37/P.
aeruginosa–treated samples with LL-37/P. aeruginosa/BIP-V5–treated
samples at corresponding concentrations **P < 0.01, ***P < 0.001.
Figure 4. Synergistic induction of apoptosis by LL-37 and P. aeruginosa
requires specific bacteria–epithelial cell interactions with whole, live
bacteria. (A) P. aeruginosa PA01 was cultured to log-phase, then
exposed to LL-37 over a range of concentrations for 1 hour at 378C
in Ultroser G serum–substitute supplemented media. Serial dilutions
were performed, incubated on LB agar plates in triplicate, and cultured
for 16 hours before colony-forming units were counted. Data represent
mean values 6 SEM, for n 5 3 independent experiments for each
condition. (B) Human bronchial epithelial cells (16HBE14o2) were
assessed for mitochondrial membrane depolarization using Mitocap-
ture dye, as described in MATERIALS AND METHODS, after incubation for
1 hour with a range of concentrations of LL-37, in serum-substitute
supplemented media, in the presence and absence of live log-phase
P. aeruginosa PA01 (MOI 10:1), heat-killed or UV-killed PA01 (MOI
10:1), P. aeruginosa PA01 LPS (1 mg/ml), P. aeruginosa PA01 condi-
tioned medium, or live P. aeruginosa PA01 (MOI 10:1) separated from
the cells via a semipermeable polyester membrane with 0.4-mm pore
size. Data represent mean values 6 SEM, for n 5 3 independent
experiments for each condition. Two-way ANOVAs were performed to
evaluate significance, with Bonferroni post hoc tests comparing LL-37
alone to LL-37/stimuli. ***P < 0.001.
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in airway epithelial cells, confirming previous findings in
alveolar epithelial cells (18). In addition, the LL-37–mediated
induction of mitochondrial depolarization and the subsequent
apoptosis of these cells can be completely blocked using the
BIP-V5 peptide inhibitor of the proapoptotic Bcl-2 family
protein Bax. The BIP-V5 peptide mimics the Bax-binding
domain of Ku70, preventing Bax translocation from cytosol to
the mitochondria (37). This translocation is a central event in
mitochondria-dependent apoptosis, with the subsequent activa-
tion and oligomerization of Bax and Bak resulting in either the
nonspecific rupture of, or the formation of specific channels in,
the outer mitochondrial membrane and release of cytochrome c
(38). Interestingly, we demonstrate that the Bax-dependent LL-
37–mediated release of cytochrome c did not cause an activa-
tion of caspase-3 or caspase-9 after exposure to LL-37 alone, yet
resulted in a Bax-dependent DNA fragmentation. In addition,
polycaspase inhibition resulted in only a partial inhibition of the
apoptosis induced by high levels of LL-37 (15). These data
suggest that the induction of apoptosis by high concentrations of
LL-37 alone appears to be a Bax-dependent and predominantly
caspase-independent process, and may implicate the liberation
and activation of mitochondrial apoptosis–inducing factor
(AIF) and/or endonuclease G. The mechanism by which LL-
37 can interact with or activate Bax in airway epithelial cells is
unclear. LL-37 could induce an opening of the mitochondrial
permeability transition pore, as proposed for bovine myeloid
antimicrobial peptide-28 (BMAP-28) (36). However, a study
published during preparation of our manuscript described
a calpain-dependent mechanism of LL-37–mediated Bax trans-
location to the mitochondria, responsible for the AIF-mediated
apoptosis induced by very high concentrations (50–200 mg/ml)
of LL-37 in Jurkat T leukemia cells. These findings are
compatible with our data (21). Irrespective of this, we demon-
strate that concentrations of LL-37 considered to be physiolog-
ically relevant during lung inflammation (10–30 mg/ml)
induce minimal apoptosis in human airway epithelial cell lines
and primary cells, in the absence of infection. This result
suggests that under normal physiological conditions, LL-37 on
epithelial surfaces would not be damaging.
In contrast to the effects of LL-37 alone, cells infected with
P. aeruginosa demonstrated an enhanced susceptibility to the
induction of apoptosis upon exposure to concentrations of LL-
37 that had no effect alone, but not to control scrambled LL-37
peptide. This effect comprised a pronounced synergistic in-
crease in mitochondrial depolarization, cytochrome c release,
and DNA fragmentation, and was at least partly Bax-independent.
In addition, the LL-37–mediated activation of caspase-3 and
caspase-9 was evident only in infected cells, demonstrating
activation of the intrinsic pathway of apoptosis. Although
P. aeruginosa infection alone has been shown to induce
extrinsic pathways of apoptosis via CD95/CD95L (12), we saw
no activation of capase-8 and no significant cell death in
response to bacteria alone in our system. This finding may
relate to the fairly low MOI used, and the timeframe examined
in our studies, suggesting that the LL-37–mediated induction of
apoptosis in infected epithelial cells is a much earlier (and
mechanistically distinct) form of cell death compared with pre-
viously described, bacterially induced death receptor–mediated
apoptosis. The intrinsic pathway of apoptosis is a mitochondrial-
dependent mechanism of caspase activation involving cyto-
chrome c–induced oligomerization of the cytosolic apoptotic
protease activating factor-1 (Apaf-1), which recruits and acti-
vates procaspase-9, an upstream activator of effector caspases,
such as caspase-3 (39). In addition, the mitochondrial release of
Smac/DIABLO (second mitochondrial activator of capases/
direct IAP binding protein with low PI) (40) and Omi (also
known as high temperature requirement factor A2 [HtrA2])
(41) leads to an inactivation of the inhibitor-of-apoptosis pro-
teins (IAPs) that normally inhibit caspase activity. The in-
creased apoptosis observed via TUNEL assay in infected cells
exposed to LL-37 could be inhibited by the polycaspase in-
Figure 5. Synergistic induction of apoptosis by LL-37 and P. aeruginosa
is isolate-specific and independent of type III secretion system and pilus
expression. Human bronchial epithelial cells (16HBE14o2) were
assessed for mitochondrial membrane depolarization using Mitocap-
ture dye, as described in MATERIALS AND METHODS, after incubation for
1 hour with a range of concentrations of LL-37, in Ultroser G serum–
substitute supplemented media, in the presence and absence of (A)
log-phase clinical P. aeruginosa isolate J1386 (MOI 10:1), (B) log-phase
P. aeruginosa PA01exsATV or isogenic PAO1 control strain (MOI 10:1),
and (C) log-phase pilA P. aeruginosa mutant or isogenic PAO1 control
strain (MOI 10:1). Data represent mean values 6 SEM, for n 5 3
independent experiments for each condition. Two-way ANOVAs were
performed to evaluate significance, with Bonferroni post hoc tests
comparing (A) LL-37/P. aeruginosa to LL-37 alone, and (B) LL-37/P.
aeruginosa mutant to LL-37/isogenic controls. *P < 0.05,***P < 0.001.
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hibitor Z-VAD-FMK, reducing it to levels similar to those
induced by LL-37 alone. Thus the synergistic effects are caspase-
dependent, and occur in addition to predominantly caspase-
independent pathways induced by higher concentrations of LL-
37 alone. The caspase inhibition by IAPs may be reduced in
infected cells, and although XIAP levels were unaffected, the
roles of Smac/DIABLO and Omi HtrA2 in this system remain
unknown. Therefore, a caspase-dependent pathway downstream
of mitochondrial depolarization, induced by an alternate mech-
anism from that used by LL-37 alone, is responsible for the
capacity of LL-37 to promote the apoptosis of cells infected
with P. aeruginosa.
The nature of the interaction between epithelial cells and
bacteria required to make these cells susceptible to the
apoptosis-inducing effects of LL-37 was investigated under a
number of conditions and using mutants of P. aeruginosa. Neither
dead bacteria nor soluble products produced by untreated or
LL-37–treated bacteria could promote these synergistic effects.
In the absence of physical contact between the epithelial cells
and live bacteria, no effects were observed. In contrast, the
effect of LL-37 was even more profound when a clinical strain
of P. aeruginosa J1386 (isolated from an individual with cystic
fibrosis) (23) was used, suggesting that this effect might be
modified by isolate variation in virulence factors. PAO1 is
classified as an ‘‘invasive’’ rather than ‘‘cytotoxic’’ strain of
P. aeruginosa (although both can invade eukaryotic cells), and
this invasiveness is proposed to require contact between bacte-
ria and epithelial cells to stimulate the efflux of bacterial
‘‘invasive factors’’ (28). The DmexAB-oprM deletion mutant
of P. aeruginosa PAO1 (24) is defective in terms of epithelial-
cell invasion (despite normal adherence), and has diminished
virulence in vivo as a consequence of the loss of the MexAB-
OprM efflux system, proposed to be responsible for the efflux of
these putative ‘‘invasive factors’’ (28). A synergistic induction of
apoptosis was not evident in LL-37–treated epithelial cells
infected with this mutant strain, but could be replicated by
the addition of these unknown ‘‘invasive factors’’ from the
isogenic wild-type PAO1 strain, demonstrating a requirement
for invasiveness. In contrast, the PAO1exsATV mutant (25), in
which the ExsA mutation impairs the ExsA-regulated type III
secretion system, behaved identically to its isogenic wild-type
PAO1 strain. Although a functional ExsA allele is required for
P. aeruginosa–induced cytotoxicity, epithelial-cell invasiveness
is independent of ExsA expression (42). Similarly, a P. aerugi-
nosa pilA mutant (26) was largely able to synergize with LL-37
to induce apoptosis as effectively as its isogenic PAO1 wild-type
strain. In this strain, pilAmutation results in an absence of pilus,
proposed to be an important adhesin involved early in epithe-
lial-cell interactions with P. aeruginosa (43). Interestingly,
differences were observed in the sensitivity to the LL-37–
induced mitochondrial depolarization of cells infected with
our original PAO1 isolate, compared with isogenic controls
for some of the mutants used. Additional investigations using
these isolates may help in further defining the key events
involved in this interaction. Nevertheless, the data suggest that
the bacterial invasion of airway epithelial cells, but not ExsA-
regulated type III secretion or pili expression, is critical in
inducing enhanced susceptibility to LL-37–mediated apoptosis.
Our results describe a novel innate inflammomodulatory role
for LL-37, preferentially inducing the apoptosis of infected
epithelial cells. However, the extent to which this might
contribute to innate epithelial defenses, or be manifest in
pathologic damage to epithelial-barrier integrity, is unknown,
and a fine balance could exist. Although LL-37 clearly has
important roles in innate host defense against infection, chron-
ically increased hCAP-18/LL-37 concentrations in cystic fibrosis
Figure 6. Synergistic induction of apoptosis by LL-37 and P. aeruginosa
requires epithelial-cell internalization of bacteria. Human bronchial
epithelial cells (16HBE14o2) were incubated for 60 minutes in Ultroser
G serum–substitute supplemented media, in the presence and absence
of (MOI 10:1) log-phase P. aeruginosa strains PA01, DmexAB-oprM
mutant (A–C ), isogenic PAO1 control strain (B), or DmexAB-oprM
mutant added concurrently with sterile conditioned supernatant col-
lected from 16HBE14o2 cells infected with PA01 (C ). (A) Invasion of
epithelial cells by bacteria was determined by gentamicin exclusion,
quantifying the number of viable CFUs surviving extracellular genta-
micin treatment (50 mg/ml). Data are plotted as mean values 6 SEM,
for n 5 3 independent experiments plated in duplicate for each
condition. (B, C ) Infected epithelial cells were concurrently incubated
with a range of concentrations of LL-37, and mitochondrial membrane
depolarization was determined using Mitocapture dye, as described in
MATERIALS AND METHODS. Data represent mean values 6 SEM, for n 5 3
independent experiments for each condition. Two-way ANOVAs were
performed to evaluate significance, with Bonferroni post hoc tests
comparing (B) LL-37/DmexAB-oprM mutant to LL-37/isogenic controls,
and (C ) LL-37/DmexAB-oprM mutant to LL-37/DmexAB-oprM mutant in
PAO1-conditioned supernatant. **P < 0.01,***P < 0.001.
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lung disease are correlated with increased lung damage (34),
and elevated hCAP-18/LL-37 concentrations are associated
with bronchiolitis obliterans syndrome (44) and the pathogen-
esis of psoriasis (45). Pulmonary epithelial-cell apoptosis plays
a significant role in P. aeruginosa clearance from the murine
lung (12). In addition, bladder epithelial-cell exfoliation after
bacterial attachment plays a role in innate defense against
invasive Escherichia coli (14), preventing the establishment of
a safe niche and intracellular biofilm-like growth (46). Further-
more, the susceptibility of individuals with cystic fibrosis to
pulmonary P. aeruginosa infection is proposed to relate, in part,
to the failure of airway epithelial cells to internalize this
bacterium, and thus an inability to clear P. aeruginosa by
desquamation of infected cells (27). Thus, we propose that in
the healthy host, LL-37, up-regulated during infection and
inflammation, may promote the apoptosis and consequent
clearance of P. aeruginosa–infected airway epithelial cells, as
a component of the innate host defense against this pathogen.
However, under pathologic conditions of excessive, chronic LL-
37 exposure, or a failure of epithelial-cell internalization of P.
aeruginosa (such as in cystic fibrosis), the epithelial-cell death
induced by high concentrations of LL-37 alone may be detri-
mental to the host and contribute to chronic lung damage. The
extent to which this effect might be common to other invasive
bacteria, or else specific to P. aeruginosa, remains to be
determined, but has clear significance for the possible use of
LL-37 and related CHDPs as antimicrobial therapeutics.
Author Disclosure: P.G.B. has received sponsored grants from Asthma UK
($1,001–$5,000). J.R.W.G. has received compensation from the Transave Corp.
for consultancies ($5,001–$10,000), has served on the board of Bayer (up to
$1,000), and has received industry-sponsored grants from Transave Corp (more
than $100,001) and from the Cystic Fibrosis Trust (more than $100,001). A.J.S.
received lecture fees from GlaxoSmithKline (up to $1,000). None of the other
authors has a financial relationship with a commercial entity that has an interest
in the subject of this manuscript.
Acknowledgments: The authors thank Dieter Gruenert and the University of
California, San Francisco, Department of Laboratory Medicine, for 16HBE14o2
cells; Keith Poole, Dara Frank, and Eva Lorenz for P. aeruginosa strains; and Robert
Morgan, Manjeet Bains, Ivan Villanueva, Cathy Doherty, Alan Brown, Hsin-Ni Li,
Adriano Rossi, Ian Dransfield, Simon Brown, Kev Dhaliwal, Olga Lucia Moncayo
Nieto, Andy Conway Morris, Mark Marsden, Fiona Rossi, Sharon Hannah, and
Sarah Fox for advice and assistance.
References
1. Zanetti M. Cathelicidins, multifunctional peptides of the innate immu-
nity. J Leukoc Biol 2004;75:39–48.
2. Bowdish DM, Davidson DJ, Hancock REW. Immunomodulatory prop-
erties of defensins and cathelicidins. Curr Top Microbiol Immunol
2006;306:27–66.
3. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of
antibacterial peptides in patients with morbus Kostmann: an obser-
vation study. Lancet 2002;360:1144–1149.
4. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune
defense system. J Allergy Clin Immunol 2008;122:261–266.
5. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA,
Pestonjamasp V, Piraino J, Huttner K, Gallo RL. Innate antimicro-
bial peptide protects the skin from invasive bacterial infection. Nature
2001;414:454–457.
6. Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, Kagnoff MF.
Cathelicidin mediates innate intestinal defense against colonization
with epithelial adherent bacterial pathogens. J Immunol 2005;174:
4901–4907.
7. Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I,
Hokfelt T, Gudmundsson GH, Gallo RL, Agerberth B, et al. The
antimicrobial peptide cathelicidin protects the urinary tract against
invasive bacterial infection. Nat Med 2006;12:636–641.
8. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidin-deficient
(cnlp 2/2) mice show increased susceptibility to Pseudomonas aerugi-
nosa keratitis. Invest Ophthalmol Vis Sci 2007;48:4498–4508.
9. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmen-
tation of innate host defense by expression of a cathelicidin antimi-
crobial peptide. Infect Immun 1999;67:6084–6089.
10. Davidson DJ, Currie AJ, Speert DP. Pseudomonas aeruginosa infections
in individuals with cystic fibrosis: North American perspective. In:
Hauser A, Rello J, editors. Severe infections caused by Pseudomonas
aeruginosa. Norwell: Kluwer Academic Publishers; 2003. pp. 71–89.
11. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW.
Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005;77:
451–459.
12. Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang
F, Weller M, Gulbins E. CD95/CD95 ligand interactions on epithelial
cells in host defense to Pseudomonas aeruginosa. Science 2000;290:
527–530.
13. Cannon CL, Kowalski MP, Stopak KS, Pier GB. Pseudomonas aerugi-
nosa-induced apoptosis is defective in respiratory epithelial cells
expressing mutant cystic fibrosis transmembrane conductance regu-
lator. Am J Respir Cell Mol Biol 2003;29:188–197.
14. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC,
Heuser J, Hultgren SJ. Induction and evasion of host defenses by
type 1–piliated uropathogenic Escherichia coli. Science 1998;282:
1494–1497.
15. Barlow PG, Li Y, Wilkinson TS, Bowdish DM, Lau YE, Cosseau C,
Haslett C, Simpson AJ, Hancock REW, Davidson DJ. The human
cationic host defense peptide LL-37 mediates contrasting effects on
apoptotic pathways in different primary cells of the innate immune
system. J Leukoc Biol 2006;80:509–520.
16. Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide,
human CAP18/LL-37, suppresses neutrophil apoptosis via the activa-
tion of formyl-peptide receptor–like 1 and P2X7. J Immunol 2006;176:
3044–3052.
17. Lau YE, Bowdish DM, Cosseau C, Hancock REW, Davidson DJ.
Apoptosis of airway epithelial cells: human serum sensitive in-
duction by the cathelicidin LL-37. Am J Respir Cell Mol Biol 2006;
34:399–409.
18. Aarbiou J, Tjabringa GS, Verhoosel RM, Ninaber DK, White SR,
Peltenburg LT, Rabe KF, Hiemstra PS. Mechanisms of cell death
induced by the neutrophil antimicrobial peptides alpha-defensins and
LL-37. Inflamm Res 2006;55:119–127.
19. Zhang Z, Cherryholmes G, Shively JE. Neutrophil secondary necrosis is
induced by LL-37 derived from cathelicidin. J Leukoc Biol 2008;84:
780–788.
20. Bjo¨rstad A˚, Askarieh G, Brown KL, Christenson K, Forsman H,
Onnheim K, Li HN, Teneberg S, Maier O, Hoekstra D, et al. The
host defence peptide LL-37 selectively permeabilises apoptotic leu-
kocytes. Antimicrob Agents Chemother 2009;53:1027–1038.
21. Mader JS, Mookherjee N, Hancock REW, Bleackley RC. The human
host defense peptide LL-37 induces apoptosis in a calpain- and
apoptosis-inducing factor-dependent manner involving Bax activity.
Mol Cancer Res 2009;7:689–702.
22. Gough M, Hancock REW, Kelly NM. Antiendotoxin activity of cationic
peptide antimicrobial agents. Infect Immun 1996;64:4922–4927.
23. Govan JR, Nelson JW. Microbiology of lung infection in cystic fibrosis.
Br Med Bull 1992;48:912–930.
24. Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are
substrates for the multidrug efflux pumps of Pseudomonas aeruginosa.
Antimicrob Agents Chemother 1998;42:399–403.
25. Frank DW, Nair G, Schweizer HP. Construction and characterization of
chromosomal insertional mutations of the Pseudomonas aeruginosa
exoenzyme S trans-regulatory locus. Infect Immun 1994;62:554–563.
26. Lorenz E, Chemotti DC, Vandal K, Tessier PA. Toll-like receptor 2
represses nonpilus adhesin-induced signaling in acute infections with
the Pseudomonas aeruginosa pila mutant. Infect Immun 2004;72:
4561–4569.
27. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance
regulator is an epithelial cell receptor for clearance of Pseudomonas
aeruginosa from the lung. Proc Natl Acad Sci USA 1997;94:12088–
12093.
28. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S,
Kamihira S, Hancock REW, Speert DP. Multidrug efflux systems play
an important role in the invasiveness of Pseudomonas aeruginosa.
J Exp Med 2002;196:109–118.
29. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT,
Schauber J, Wu K, Meinken C, et al. Toll-like receptor triggering of
a vitamin D–mediated human antimicrobial response. Science 2006;
311:1770–1773.
30. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW,
Skolimowska K, Davidson RN, Sorensen OE, Kampmann B, Griffiths
CJ, et al. IFN-fgammag– and TNF-independent vitamin D–inducible
Barlow, Beaumont, Cosseau, et al.: LL-37 Promotes Apoptosis of Infected Airway Epithelium 701
human suppression of mycobacteria: the role of cathelicidin LL-37.
J Immunol 2007;178:7190–7198.
31. Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M,
Wheelwright M, Vazirnia A, Zhang X, Steinmeyer A, Zugel U,
et al. Convergence of IL-1beta and VDR activation pathways in
human TLR2/1-induced antimicrobial responses. PLoS One 2009;
4:e5810.
32. Rosenberger CM, Gallo RL, Finlay BB. Interplay between anti-
bacterial effectors: a macrophage antimicrobial peptide impairs in-
tracellular salmonella replication. Proc Natl Acad Sci USA 2004;101:
2422–2427.
33. Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial
peptides in tracheal aspirates of newborn infants during infection. Am
J Respir Crit Care Med 2002;165:992–995.
34. Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R. Beta-defensins and
LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis.
J Cyst Fibros 2004;3:45–50.
35. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M,
Thompson A, Wang A, Lee K, Doria S, Hamill P, et al. An anti-
infective peptide that selectively modulates the innate immune
response. Nat Biotechnol 2007;25:465–472.
36. Risso A, Braidot E, Sordano MC, Vianello A, Macri F, Skerlavaj B,
Zanetti M, Gennaro R, Bernardi P. BMAP-28, an antibiotic peptide
of innate immunity, induces cell death through opening of the
mitochondrial permeability transition pore. Mol Cell Biol 2002;22:
1926–1935.
37. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable
peptides designed from the BAX-binding domain of KU70. Nat Cell
Biol 2003;5:352–357.
38. Martinou JC, Desagher S, Antonsson B. Cytochrome c release from
mitochondria: all or nothing. Nat Cell Biol 2000;2:E41–E43.
39. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell
death. Natl Rev 2007;8:405–413.
40. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE,
Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO,
a mammalian protein that promotes apoptosis by binding to and
antagonizing IAP proteins. Cell 2000;102:43–53.
41. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi
R. A serine protease, HTRA2, is released from the mitochondria
and interacts with XIAP, inducing cell death. Mol Cell 2001;8:
613–621.
42. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE,
Kanada D, Sawa T, Yen TS, Frank DW. Pseudomonas aeruginosa–
mediated cytotoxicity and invasion correlate with distinct geno-
types at the loci encoding exoenzyme S. Infect Immun 1997;65:
579–586.
43. Hahn HP. The type-4 pilus is the major virulence-associated adhesin of
Pseudomonas aeruginosa—a review. Gene 1997;192:99–108.
44. Anderson RL, Hiemstra PS, Ward C, Forrest IA, Murphy D, Proud D,
Lordan J, Corris PA, Fisher AJ. Antimicrobial peptides in lung
transplant recipients with bronchiolitis obliterans syndrome. Eur
Respir J 2008;32:670–677.
45. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B,
Cao W, Wang YH, Su B, Nestle FO, et al. Plasmacytoid dendritic cells
sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:
564–569.
46. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ.
Intracellular bacterial biofilm–like pods in urinary tract infections.
Science 2003;301:105–107.
702 AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL 43 2010
